Stay updated with breaking news from Fibrosis Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu, a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasisNew analysis to be presented at the 2022 European Academy of Dermatology and Venereology Cong...
Results showed improved or preserved cognitive function in a majority of people regardless of baseline values, with the greatest effect observed in almost 80% of people with high thalamic volume (45.5%
Press release content from Business Wire. The AP news staff was not involved in its creation.
Deucravacitinib showed statistically significant efficacy at primary endpoint of Systemic Lupus Erythematosus (SLE) Responder Index-4 (SRI(4)) responses versus placebo at Week 32 Secondary endpoints
Treatment with deucravacitinib was associated with long-term efficacy and safety in adults with moderate to severe plaque psoriasis.